Industry: Pharmaceuticals, Biotechnology
Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development programs are currently in Phase 1 clinical trials for evaluation of safety in patients with diabetic neuropathy and peripheral artery disease. Other therapeutic development programs are focused on ischemic heart disease, neuropathic pain, cancer and infectious and monogenic diseases. Sangamo’s core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA- binding proteins ( www.sangamo.com )
Sangamo BioSciences , Inc.
Pt. Richmond Tech Center II 501 Canal Blvd, Suite A100
Richmond, California 94804
USA
Tel: (510) 970-6000
Fax: (510) 236-8951